Knowledge management in R&D centres, in the field of biomedicine, using contemporary information and communication technology and the methodology of continuous improvement

• Main Author: Ryszard Depta
• Format: Article
• Language: English
• Published: The Institute of Aviation 2015-09-01
• Series: Marketing of Scientific and Research Organisations
• Subjects: biomedicine; ICT; knowledge management; marketing; minib; research and development institutions; tools for continuous improvement
• Online Access: http://minib.pl/en/knowledge-management-in-rd-centres-in-the-field-of-biomedicine-using-contemporary-information-and-communication-technology-and-the-methodology-of-continuous-improvement/

Some sophisticated medical applications, including advanced therapeutics with monoclonal antibodies, stem cells, and gene therapies are currently available in clinical trials. More revolutionary technologies are coming soon and will be marketed by the best technically advanced companies in the world. R&D companies with a much smaller indicator of technological progress and organizational efficiency, but with a great desire to become a major player in this industry, will also compete for a share of this market. However, in order to become a fixture in the changes initiated, both must constantly learn and be more innovative. In the current market situation, a hypercompetitive economy with the entrepreneurs’ focus on the prosumer, creativity is becoming extremely important in achieving final success. Creativity, which is the result of proper knowledge management, especially in science. The market value of R&D companies and their further future depends to a large extent on the prosperity of knowledge transfer. The most important role in the process of knowledge transfer is played by information and communication technologies (ICT) and tools for continuous improvement. If companies implement these efficiently and safely, they can develop and benefit from competitive advantages for a very long period of time. Such an approach would give them the possibility of reducing the cost and time to deliver new products to market, and create a new platform to generate innovative products. This is a new perspective for R&D businesses, and a great opportunity for institutions in the biomedical arena to become part of the upcoming bio-revolution.